Breaking Finance News

A statement released earlier today by Robert W. Baird about BeiGene (NDAQ:BGNE) bumps the target price to $83.00

In a report released on 11/14/2017 Robert W. Baird increased the stock price target of BeiGene (NDAQ:BGNE) from $58.00 to $83.00 indicating a possible upside of 0.04%.

Previously on 08/07/2017, Ladenburg Thalmann reported on BeiGene (NDAQ:BGNE) increased the target price from $0.00 to $81.00. At the time, this indicated a possible upside of 0.04%.

Yesterday BeiGene (NDAQ:BGNE) traded -3.78% lower at $79.90. The company’s 50-day moving average is $77.30 and its 200-day moving average is $77.30. The last closing price is up 24.51% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time period. 275,902 shares of the stock traded hands, up from an average trading volume of 232,286

See Chart Below


BeiGene has a 52 week low of $26.43 and a 52 week high of $102.00 The company’s market cap is currently $0.

About BeiGene (NDAQ:BGNE)

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.